Arjo Q1 2026 slides: stable growth masks margin pressure from tariffs

Arjo posted 3.8% organic revenue growth in Q1 2026, with adjusted EBITDA of 456 million SEK and cash conversion improving to 52.7%, but gross margin fell 110 bps to 42.6% amid U.S. tariff and currency headwinds. Regional performance was mixed: North America grew 2.2%, Western Europe fell 2.9%, and Rest of World surged 30.0% on India, Hong Kong, and a major South Africa bed order. Management said a new strategy and financial targets will be presented in 2H 2026, while geopolitical tensions and margin pressure remain key risks.

Analysis

The market is treating this as a clean “beat but not enough” print, but the more important signal is that demand is proving resilient while management is admitting the margin structure is still fragile. The mix shift toward lower-margin beds in faster-growing emerging markets is a classic growth trap: it inflates revenue and backlog optics while quietly capping operating leverage. That makes the upcoming strategy reset a real catalyst, because if new targets are not accompanied by a credible mix/price/reimbursement plan, the current valuation discount can persist even with mid-single-digit growth.

The second-order winner is likely the healthcare capex ecosystem in emerging markets, not Arjo alone. Large multi-site hospital rollouts create follow-on demand for consumables, maintenance, training, and replacement cycles, which can benefit adjacent med-tech vendors with broader recurring revenue exposure. Conversely, European peers with more domestic exposure and weaker product breadth may see relative pressure if Arjo keeps winning international reference projects while incumbents remain stuck in slower hospital budgets.

Tariff and FX sensitivity are the key near-term risk over the next 1-2 quarters. If the geopolitical backdrop keeps energy and shipping costs elevated, gross margin pressure can linger even if unit volumes hold up, because this business has limited pricing power in competitive tender channels. The contrarian view is that the stock may be over-discounting the margin issue and underappreciating cash conversion improvement: if working capital remains this efficient, management has room to absorb temporary earnings noise without stressing the balance sheet.

The real inflection point is 2H26, but that also means the stock can drift for months unless there is evidence of pricing discipline or an improved regional mix in the next 2-3 prints. Any pullback tied to tariff headlines could be bought if cash generation stays strong; the thesis breaks if North America softens and Rest of World growth normalizes before the strategy update. In that scenario, the market will likely re-rate Arjo as a low-quality grower rather than a turnaround story.

Key Decisions for Investors

• Long ARJOB on weakness over the next 1-3 weeks with a 6-9 month horizon: attractive if the market is over-penalizing temporary tariff/FX noise; target a re-rating on sustained cash conversion and strategy update optionality, but keep a tight stop if gross margin loses another 100 bps.
• Pair trade: long ARJOB / short a slower-growth European med-tech or hospital-equipment peer with weaker emerging-market exposure for a 3-6 month relative-value trade; thesis is that Arjo’s ROw project pipeline and cash conversion should outperform despite headline margin pressure.
• Buy 3-6 month call spreads on ARJOB into any post-earnings drift: the convexity is in a late-2026 strategy reset plus potential margin stabilization, while downside is buffered by already-depressed sentiment.
• If you want lower risk, wait for the next quarterly update before adding: the stock likely needs evidence that mix is no longer deteriorating; absent that, upside can remain capped until management shows pricing discipline.
• Avoid chasing broad healthcare beta here; prefer idiosyncratic exposure to Arjo only if you believe the emerging-market install base will convert into recurring after-sales revenue over 12-24 months.